China TCM (570.HK) Privatization Update - Things Are Still Manageable

Xinyao has highlighted this Insight as a Top Pick
446 Views06 Aug 2024 08:55
​Investors disappointed by slow progress, but the success of privatization lies in whether CNPGC is willing to abide by its commitments.Valuation shows bottom line is HK$3.5 even without privatization
What is covered in the Full Insight:
  • Introduction
  • Current Status of Privatization
  • Challenges and Investor Concerns
  • Financial Analysis
  • Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x